Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06188520
Title A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)
Acronym CYCAD-1
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | AUS

No variant requirements are available.